# PRTX007

Source: https://onco.cc/drugs/prtx007/  
OnCo record `prtx007` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PRTX007 is a small-molecule inhibitor from Primmune Therapeutics, Inc., in registered phase 2 trials for melanoma.

## Summary

PRTX007 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Primmune Therapeutics, Inc., in melanoma. Described in the registry record as a small-molecule inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: PRTX007
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a small-molecule inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of PRTX007: https://clinicaltrials.gov/search?intr=PRTX007

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- trials: [The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma](https://onco.cc/trials/nct07565285/)

---
JSON: https://onco.cc/api/v1/entities/prtx007.json